DRUG
benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
300 mg of powder form dissolved in one cup of tap water prior to breath test
Status
Completed
Phase
Phase 2
Enrollment
33
Locations
1
Results
Not posted
Publications
0
Study summary
13C breath di-peptide tests are an effective non-invasive tool to detect pancreatic exocrine function in patients with Chronic Pancreatitis.
The aim of the study is to assess the pancreatic exocrine insufficiency using a 13C labeled di-peptide breath tests in patients with chronic pancreatitis(CP) and show correlation with secretin stimulated endoscopic Pancreatic Function Test (ePFT). Furthermore, a second purpose is to assess the ability to differentiate between non patients with chronic pancreatitis and those without. Approximately 30 subjects will be tested with both methods within two weeks of each other.
Interventions
DRUG
300 mg of powder form dissolved in one cup of tap water prior to breath test
DRUG
300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
Timeline
First posted
Dec 14, 2010
Study start
Jan 2009
Primary completion
Feb 2009
Study completion
Mar 2009
Results posted
Not reported
Registry updated
Dec 20, 2022
Outcomes
To assess the pancreatic exocrine insufficiency using a 13C labeled di-peptide breath tests in patients with chronic pancreatitis(CP) and show correlation with secretin stimulated endoscopic Pancreatic Function Test (ePFT).
Time frame · 1 hour
This breath test substrate is new and is hypothesized, based on preliminary studies, that it may be the answer to a much needed non-invasive pancreatic function test. At first stage, it will be compared to the current invasive gold standard: secretin induced ePFT.
To assess the ability to differentiate between non patients with chronic pancreatitis and those without.
Time frame · 1 hour
In order to establish the efficacy of this test, it is necessary to confirm that a difference is observed between healthy and non- healthy subjects
Eligibility
Inclusion Criteria: 1. Patients with chronic pancreatitis who meet at least one of the following criteria: * Adult men or women \>18 years of age. * Endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP), or endoscopic ultrasound demonstrating ductal changes consistent with chronic pancreatitis * Abnormal secretin pancreatic function test with a peak bicarbonate concentration \<80 mEq/L * Presence of pathogenomic pancreatic calcifications * Pathology proven chronic pancreatitis on surgical specimens 2. Females of childbearing potential must be willing to use birth control (IUD, oral, transdermal, parenteral contraceptives, or abstinence) 3. Patients who can fast for at least 8 hours 4. Able to perform the testing and procedures required for the study, as judged by the investigator 5. Willing and able to provide written informed consent Exclusion Criteria: * Failure to obtain consent * Patients with liver cirrhosis * Any co-morbid condition with expected survival \< 1 year * History of extensive bowel resection, multiple abdominal surgeries * Women who are pregnant, breastfeeding, or of childbearing potential and not willing to use methods of birth control * Uncontrolled diabetes * Patients currently receiving total parenteral nutrition (TPN) * Recipients of an organ transplant * Patients who have consumed \>20cc of alcohol or have taken acetaminophen in the past 24 hours * History of chronic obstructive pulmonary disease or symptomatic bronchial asthma * Patients taking drugs that can interfere with 13C di-peptide metabolization
Study locations
India. Showing up to 24 locations stored in the fast local snapshot.
Asian Institute of Gastroenterology, Hyderabad, India
Somājigūda, Hyderabad, India
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.